Panobinostat

Panobinostat
Clinical data
Trade namesFarydak
Other namesLBH-589
AHFS/Drugs.comMonograph
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • US: ℞-only[2]
  • EU: Rx-only[3]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability21%[2]
Protein binding90%[2]
MetabolismCYP3A (40%), CYP2D6, CYP2C19[2]
Elimination half-life37 hours[2]
ExcretionFecal (44–77%), renal (29–51%)[2]
Identifiers
  • (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.230.582 Edit this at Wikidata
Chemical and physical data
FormulaC21H23N3O2
Molar mass349.434 g·mol−1
3D model (JSmol)
  • O=C(NO)\C=C\c1ccc(cc1)CNCCc3c2ccccc2[nH]c3C
  • InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+ ☒N
  • Key:FPOHNWQLNRZRFC-ZHACJKMWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of multiple myeloma.[2][3] It is a hydroxamic acid[4] and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).[5]

Panobinostat was approved for medical use in the United States in February 2015,[2][6][7] and in the European Union in August 2015.[3][8] However, in March 2022, it was withdrawn in the United States.[9][10]

  1. ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
  2. ^ a b c d e f g h "Farydak- panobinostat capsule". DailyMed. 27 July 2021. Retrieved 22 October 2022.
  3. ^ a b c "Farydak EPAR". European Medicines Agency. 17 September 2018. Retrieved 22 October 2022.
  4. ^ Cite error: The named reference Revill2007 was invoked but never defined (see the help page).
  5. ^ Table 3: Select epigenetic inhibitors in various stages of development Archived 18 April 2016 at the Wayback Machine from Mack GS (December 2010). "To selectivity and beyond". Nature Biotechnology. 28 (12): 1259–66. doi:10.1038/nbt.1724. PMID 21139608. S2CID 11480326.
  6. ^ "Farydak Drug Approval Package". U.S. Food and Drug Administration (FDA). 17 March 2015. Retrieved 22 October 2022.
  7. ^ "Drug Trials Snapshot: Farydak (panobinostat)". U.S. Food and Drug Administration (FDA). 30 July 2020. Retrieved 22 October 2022.
  8. ^ "Farydak product details". European Medicines Agency. 17 September 2018. Archived from the original on 20 June 2018. Retrieved 1 February 2017.
  9. ^ "Withdrawn Oncology /Hematologic Malignancies Accelerated Approvals". U.S. Food and Drug Administration (FDA). 1 June 2022. Retrieved 22 October 2022.
  10. ^ "Secura Bio, Inc.; Withdrawal of Approval of New Drug Application for Farydak (panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams". Federal Register. 24 March 2022. Retrieved 22 October 2022.